A phase II study (24) focused on the clinical benefit of combining the anti-PD-L1 antibody camrelizumab with oxaliplatin-based chemotherapy (FOLFOX or GEMOX) in HCC patients and found an ORR of 26.5%, a DCR of 79.4%, a median TTR of 2.0 months, and a median PFS of 5.5 months. This evidence concerns the gene CD274 and hepatocellular carcinoma.